Ipilimumab and Nivolumab With CRT May Be a Bladder-Sparing Treatment in MIBC - Oncology Nurse Advisor The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

Combined neoadjuvant treatment with ipilimumab and nivolumab followed by CRT shows promise as a bladder-sparing treatment for muscle-invasive #bladdercancer. From @natmed.nature.com and @renalurologynews.bsky.social.

Read more: ➡️ https://bit.ly/3MZPjiH

#MIBC #blcsm #UroOnc

Dr Galsky on the Design of the KEYNOTE-B15 Trial in MIBC | OncLive Matthew D. Galsky, MD, unpacks the design of the phase 3 KEYNOTE-B15 in patients with MIBC.

📹 @mattgalsky.bsky.social of @mountsinainyc.bsky.social unpacks the design of the phase 3 KEYNOTE-B15 in patients with MIBC. #oncology #medtwitter #MIBC #bladdercancer
Watch here: www.onclive.com/view/dr-gals...

Dr Galsky on the Background of the KEYNOTE-B15 Trial in MIBC | OncLive Matthew D. Galsky, MD, discusses the background of the phase 3 KEYNOTE-B15 trial in muscle-invasive bladder cancer.

📹 Watch Matthew D. Galsky, MD, of @mountsinainyc.bsky.social, shed light on the background of the phase 3 KEYNOTE-B15 trial in muscle-invasive bladder cancer. @ascocancer.bsky.social #GU26 #oncology #MIBC

www.onclive.com/view/dr-gals...

Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results PURPOSEStandard of care for muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC) with neoadjuvant cisplatin-based chemotherapy (NAC). However, many patients are ineligible for or refuse ci...

Sistema de gemcitabina intravesical más cetrelimab aumenta la respuesta completa patológica y general y la supervivencia libre de recurrencia a un año en pacientes con cáncer de vejiga con invasión muscular #MIBC #gemcitabin ascopubs.org/doi/full/10....

Gem-iDRS + Cetrelimab Does Not Improve Survival in MIBC Gemcitabine intravesical system+intravenous cetrelimab did not improve bladder-intact event-free survival or OS for pts with MIBC who did not receive radical cystectomy.

In patients with #MIBC who did not undergo radical cystectomy, treatment with gemcitabine intravesical system plus cetrelimab did not show superior efficacy over concurrent chemoradiation therapy, according to research published at #GU26.

ASCO GU 2026: Are Combinatorial Therapies the Future Standard of Care in RCC and MIBC? Findings presented at the 2026 ASCO GU Symposium show that combinatorial therapies may provide new treatment options for patients with renal cell carcinoma or muscle-invasive bladder cancer.

Highly anticipated results presented at #GU26 show that combinatorial therapies may provide much-needed answers for #RCC and #MIBC patient populations.

Dr. Bellmunt concludes IMvigor011:

🧬 Detectable ctDNA after RC identified higher‑risk pts, while persistent ctDNA− aligned with low risk

💉 Adjuvant atezolizumab promoted ctDNA reduction and clearance which was associated with improved DFS

#GU26 #BladderCancer #MIBC

🔬 Dr. Bellmunt presents IMvigor011: early ctDNA positivity after RC was frequent and typically detected within <24 wks

📉Baseline ctDNA levels differed by risk group, and ctDNA kinetics showed clear divergence between arms over time

#GU26 #BladderCancer #MIBC #Oncology

Can ctDNA timing and dynamics refine adjuvant treatment decisions in #MIBC?
Follow our #GU26 coverage for new insights from Joaquim Bellmunt on the IMvigor011 trial

#BladderCancer #Oncology #MedSky #MedEd

KEYNOTE‑B15: EV + pembro shows strong EFS benefit in cisplatin‑eligible MIBC
HR 0.52; 12‑mo EFS 78.2% vs 64.0% with chemo
Matthew D. Galsky notes “The EV+pembro and cis+gem curves separate at ~6 months and stay apart”
✅EFS significantly longer with EV+pembro

#GU26 #Oncology #MIBC

New research from #GU26 to share with your #BladderCancer patients: Combining enfortumab vedotin with pembrolizumab before and after surgery can help reduce risk of recurrence for some people with #MIBC.

Learn more: https://bit.ly/4rBsOzC

We’re back with more #GU26 coverage!
Today we kick-off with the latest results from the KEYNOTE-B15 study presented by Matthew D. Galsky

#BladderCancer #Oncology #MIBC #MedEd #MedSky

アステラス、PADCEV＋Keytruda周術期療法を日本でsNDA提出──シスプラチン不適格MIBCでEV-303/KEYNOTE-905に基づく | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究

Astellas submits sNDA in Japan for PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) as perioperative therapy in cisplatin-ineligible MIBC

stellanews.life/technology/8...

#BladderCancer #MIBC #EnfortumabVedotin #Pembrolizumab #EV303 #KEYNOTE905 #sNDA

🌐 #ESMODeepDive webinar: #MIBC - from evidence to practice with ctDNA, perioperative optimisation & bladder‑sparing.

Live Q&A 💬 ESMO member: register to secure your seat: 🔗 https://ow.ly/zXQK50Y5hbt

#ESMOWebinar #ESMOOnAir #BladderCancer #Oncology #PrecisionMedicine

Lars Dyrskjøt Nick James

TOMBOLA Trial: ctDNA-Guided Role of Adjuvant Immunotherapy After Cystectomy in Muscle-Invasive Bladder Cancer - OncoDaily The phase II TOMBOLA trial investigates a ctDNA-guided approach to personalize adjuvant immunotherapy after cystectomy in muscle-invasive bladder cancer, enabling early treatment escalation for molecu...

TOMBOLA Trial: ctDNA-Guided Role of Adjuvant Immunotherapy After Cystectomy in Muscle-Invasive Bladder Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TOMBOLA #BladderCancer #MIBC

Treated for muscle invasive bladder cancer and want to keep your bladder? Ask your doctor about #ClinicalTrial S2427 (BRIGHT).
SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC

Bladder removal surgery can have a big impact on quality of life. Study S2427 (also called BRIGHT) is testing a possible #BladderSparing approach for people with muscle invasive #BladderCancer. To learn more, visit SWOG.org/S2427 or call 1-800-4-CANCER. #MIBC

Perioperative Enfortumab Vedotin/Pembrolizumab Meets EFS, OS, pCR End Points in Cisplatin-Eligible MIBC | OncLive Enfortumab vedotin plus pembrolizumab is the first perioperative regimen without chemotherapy to improve both EFS and OS in cisplatin-eligible MIBC.

Perioperative Enfortumab Vedotin/Pembrolizumab Meets EFS, OS, pCR End Points in Cisplatin-Eligible MIBC #oncology #MIBC
www.onclive.com/view/periope...

SunRISe-4: Neoadjuvant Intravesical Gemcitabine Plus Cetrelimab Shows Promise in Muscle-Invasive Bladder Cancer Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic complete response in this population.

Neoadjuvant treatment with a gemcitabine intravesical system plus the PD-1 blocking antibody cetrelimab outperformed cetrelimab alone in patients with muscle-invasive #bladdercancer. Published in @ascopost.bsky.social Journal of Clinical Oncology.

https://bit.ly/4j2SvFL

#blcsm #MIBC

Are you getting treatment for muscle invasive bladder cancer? Ask your doctor about S2427 (BRIGHT). It’s a #ClinicalTrial testing whether an immunotherapy drug plus radiation therapy can help patients keep their bladder. SWOG.org/S2427. 1-800-4-CANCER. #MIBC

Why it matters for #bladdercancer care: better risk-adapted bladder-sparing strategies, smarter use of biomarkers in decision-making, and trials built around what matters most to patients & survivors. #uroonc #MIBC

Milan Consensus Endpoints for Bladder Preservation in MIBC | Podcast | ASCO Publications Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article

🎧 New #JCOAfterHours episode! Dr. Davide Soldato sits down with Dr. Andrea Necchi & Dr. Ashish Kamat to discuss their @ascocancer.bsky.social article on evolving end points for non-operative #MIBC trials and bladder-sparing strategies.

Listen here: ascopubs.org/do/milan-con...

ASCO Publications

Gemcitabina intravesical + cetrelimab proporcionan mayor respuesta completa patológica, respuesta general y supervivencia libre de recurrencia al año en pacientes c/CA vejiga con invasión muscular #gemcitabine #cetrelimab #MIBC ascopubs.org/doi/abs/10.1...

S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Focal, non-diffuse carcinoma in situ (CIS) is allowed.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: Daniel A. Hamstra, MD, PhD Baylor College of Medicine
swog.org/clinical-trials/S2427

If patients w #MIBC have a clinically sig response to NAT, is cystectomy needed? S2427 BRIGHT trial tests whether pembro + RT can let patients keep their bladder. Systematic biopsies needed at post-NAT TURBT.
Co-PI: Abhishek Tripathi, MD City of Hope
swog.org/clinical-trials/S2427

S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0/cT1) allow for bladder preservation?
Systematic biopsies needed at post-NAT TURBT pre-registration.
Co-PI: S. Daneshmand, MD USC Norris Comprehensive Cancer Center
swog.org/clinical-trials/S2427

🔗 Read more: bit.ly/ONCOnews24N-1

#ONCOnews #OncoAlert #OncEd #FDAApproval #BladderCancer #MIBC #OncologyUpdates #Immunotherapy

Consider S2427 BRIGHT for your pts with #MIBC getting neoadj therapy. If systematic biopsies at post-NAT TURBT show cT0 or cT1, pt may be eligible for S2427. Can IO + RT be bladder-preserving? #BladderCancer
PI: Leslie Ballas, MD Cedars-Sinai Cancer
swog.org/clinical-trials/S2427

Adjuvant Radiotherapy Improves Locoregional Recurrence in High-Risk MIBC - Oncology Nurse Advisor In patients with locally advanced muscle-invasive bladder cancer who have undergone radical cystectomy and chemotherapy, adjuvant radiotherapy improves survival outcomes compared to observation only.

In patients with high-risk #MIBC, the 2-year locoregional failure-free survival rate was 87.1% with radiotherapy and 76.0% with observation. From @cancertherapyadv.bsky.social.

https://bit.ly/499ZqtR

#blcsm #bladdercancer

IMvigor011 Confirms ctDNA Status as Key Predictor of Adjuvant Atezolizumab Efficacy in MIBC | OncLive Joaquim Bellmunt, MD, PhD, discusses the rationale for and findings from the IMvigor011 trial of ctDNA-guided adjuvant atezolizumab vs placebo in MIBC.

IMvigor011 Confirms ctDNA Status as Key Predictor of Adjuvant Atezolizumab Efficacy in MIBC @danafarber.bsky.social #oncology #MIBC #bladdercancer
www.onclive.com/view/imvigor...